Thomas S. Lin
Thomas S. Lin publishes mostly in Genetics, Hematology and Pathology and Forensic Medicine, on topics such as Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment and Multiple Myeloma Research and Treatments.
- World rank
- #1,280,095 of 7,710,434 ranked researchers
- Rank in United States
- #407,785 of 1,627,098
- Works
- 297
- Citations
- 8.9k
- Citations per work
- 29.9
What does Thomas S. Lin research?
Thomas S. Lin's work is mostly in Medicine (56%), Biochemistry, Genetics and Molecular Biology (8%), Immunology and Microbiology (6%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences16756.1%
- Medicine16756.1%
- Everything else8829.5%
- Life Sciences4314.4%
- 1Genetics19% of their works
- 2Hematology16% of their works
- 3Pathology and Forensic Medicine13% of their works
- 4Oncology8% of their works
- 5Molecular Biology8% of their works
- 6Immunology6% of their works
Research topics
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Acute Lymphoblastic Leukemia research
- Immunodeficiency and Autoimmune Disorders
- Chronic Myeloid Leukemia Treatments
- Monoclonal and Polyclonal Antibodies Research
- Protein Degradation and Inhibitors
Which keywords describe Thomas S. Lin's research?
The keywords of their largest research topics: Rituximab, Prognostic Factors, Chronic Lymphocytic Leukemia, Genomic Aberrations, Minimal Residual Disease, Classification, Lymphoma and Diagnosis Criteria.
- BET Bromodomains
- Fc Receptors
- BCR-ABL
- Genetic Mutations
- Acute Lymphoblastic Leukemia
- Diagnosis Criteria
- Classification
- Genomic Aberrations
- Prognostic Factors
- Rituximab
- Chronic Lymphocytic Leukemia
- Minimal Residual Disease
- Lymphoma
- International Myeloma Working Group
- Childhood Cancer
- Primary Immunodeficiency
- Imatinib
- Therapeutic Antibodies
- PROTACs
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most.
All 19 words, with their numbers
- Rituximab2632 topics
- Prognostic Factors1912 topics
- Chronic Lymphocytic Leukemia1561 topic
- Genomic Aberrations1561 topic
- Minimal Residual Disease1102 topics
- Classification1071 topic
- Lymphoma1071 topic
- Diagnosis Criteria751 topic
- International Myeloma Working Group751 topic
- Acute Lymphoblastic Leukemia351 topic
- Childhood Cancer351 topic
- Genetic Mutations341 topic
- Primary Immunodeficiency341 topic
- BCR-ABL311 topic
- Imatinib311 topic
- Fc Receptors251 topic
- Therapeutic Antibodies251 topic
- BET Bromodomains221 topic
- PROTACs221 topic
Where does Thomas S. Lin work?
Thomas S. Lin's main affiliation in the publication record is The Ohio State University, United States.
How many publications and citations does Thomas S. Lin have?
OpenAlex counts 297 works and 8,889 citations for Thomas S. Lin, an h-index of 47, ranking #1,280,095 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Thomas S. Lin. Posts are plain text and can be reported.